Quratis Inc.: Clinical Trials

4 trials sponsored by Quratis Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 1 recruiting. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Unknown 2, Recruiting 1
Phase 21Unknown 1

Follow Quratis Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
QTP101, Placebo - Tuberculosis, Pulmonary
Phase 1RecruitingQuratis Inc.1442025-05-092025-06-17
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
QTP104 1ug, QTP104 5ug, QTP104 25ug - COVID-19, SARS-CoV-2
Phase 1UnknownQuratis Inc.362021-11-192023-05-25
Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
Placebo, ID93+GLA-SE - Tuberculosis
Phase 1UnknownQuratis Inc.362019-04-022019-07-23
Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
Placebo, ID93+GLA-SE - Tuberculosis
Phase 2UnknownQuratis Inc.1072018-05-312019-05-31

Conditions studied

Tuberculosis (2)  ·  COVID-19 (1)  ·  Tuberculosis, Pulmonary (1)

Countries

South Korea (4)

Top investigators

Yu Hwa Choi (3)  ·  Jae Chol Choi, MD, PhD (1)  ·  Jinhee Lee, DVM, PhD (1)  ·  Jinsoo Min, MD, PhD (1)  ·  Joon-Sup Yeom, MD/PhD (1)  ·  Kwang Joo Park, MD, PhD (1)  ·  Young Goo Song, MD/PhD (1)  ·  Youngmok Park, MD, PhD (1)

Results publications

PMID 37166567